A recent study conducted by Dr. med. Michael Winkelmann and his colleagues at the LMU Klinikum München explored the association between TGR dynamics from pre-treatment to post-treatment imaging and the patients' outcomes.
The research provides valuable insights into the potential of TGR as a novel prognostic imaging biomarker in the context of CAR-T therapy for patients with relapsed or refractory non-Hodgkin's lymphoma.

Study with mint Lesion™ Uncovers the Impact of Tumor Growth Rate in Predicting the Efficacy of CAR-T-cell Therapy in Lymphoma Patients
Related Resources
Related Resources

Implementing RANO 2.0 for Neuro-Oncology Clinical Trials in mint Lesion
Tumor response assessment in neuro-oncology clinical trials requires careful attention to measurement protocols and confirmation scan requirements. To…

RACOON – Imaging, Data & Collaboration for Better Decisions
Modern radiology faces a central question: how can imaging and clinical data be combined in a way that leads to more precise diagnoses,…

Rethinking Early Detection: How RACOON-MARDER Aims to Spot Liver Cancer Sooner
Hepatocellular carcinoma (HCC) is often diagnosed too late, limiting treatment options and survival. The RACOON-MARDER project aims to change that. By…